IGF-1 DES

IGF-1 DES, or des(1-3)IGF-1, is a truncated analogue of insulin-like growth factor 1 lacking the first three N-terminal residues, giving a 67-amino-acid peptide against native IGF-1's 70. It is an endogenous species rather than a synthetic novelty, isolated from human brain tissue, bovine colostrum and porcine uterine tissue, and is presumed to arise from post-translational cleavage of intact IGF-1.

The functionally decisive deletion is glutamate at position 3. Its absence collapses affinity for the IGF binding proteins that normally sequester circulating IGF-1 and govern the free, receptor-available fraction. With IGFBP sequestration largely bypassed, nearly all administered peptide remains free and bioactive, producing potency in cultured cells roughly 10-fold that of native IGF-1 at stimulating growth and proliferation.

The pharmacokinetic profile separates it from the rest of the IGF-1 family: a half-life of approximately 20 to 30 minutes against 20 to 30 hours for IGF-1 LR3 and 12 to 15 hours for native IGF-1. Rapid clearance is the defining practical feature, confining meaningful exposure to tissue near the injection site and limiting sustained systemic signalling. IGF-1 DES is therefore positioned as the localised precision tool within the IGF-1 family, with IGF-1 LR3 serving the systemic role.

Regulatory status is unambiguous: no FDA approval for any indication, research-compound classification, and prohibition by WADA under Peptide Hormones, Growth Factors, and Related Substances.

IGF-1 DES signals through the same tyrosine kinase IGF-1 receptor (IGF-1R) as native IGF-1; the distinction lies upstream of receptor engagement.

Native IGF-1 circulates predominantly IGFBP-bound, with binding proteins setting the free, bioactive fraction. Loss of the N-terminal tripeptide, and specifically glutamate at position 3, drops IGFBP affinity sharply. Ross and colleagues (1989) demonstrated that IGFBPs inhibited DNA synthesis, protein accumulation and anti-proteolytic activity of IGF-1 and IGF-2 in culture while leaving des(1-3)IGF-1 entirely unaffected, with biological potency correlating inversely with binding protein affinity.

Downstream signalling is conventional. PI3K-Akt-mTOR drives protein synthesis, glucose uptake, cell growth and resistance to apoptosis. MAPK drives proliferation and differentiation, underpinning satellite cell activation and the theoretical potential for new fibre formation.

The 20 to 30 minute half-life is what converts this pharmacology into a site-specific tool. Clearance occurs before meaningful systemic distribution, so intramuscular delivery concentrates IGF-1R activation in the injected tissue rather than producing whole-body signalling as IGF-1 LR3 does over 20 to 30 hours.

Ballard and colleagues (1987) established that des(1-3)IGF-1 was approximately 7 times more potent than native IGF-1 at stimulating protein synthesis in L6 myoblasts, with essentially unchanged receptor affinity, confirming that potency derives from escape of IGFBP sequestration. The 1996 review by the same group revised the estimate to roughly 10-fold for hypertrophy and proliferation of cultured cells, noting that enhanced effectiveness persists partially in vivo, particularly in gut tissue.

Functionally, IGF-1 DES is a localised anabolic stimulus. Intramuscular delivery into a target muscle produces concentrated IGF-1R activation, driving local protein synthesis and satellite cell recruitment before clearance, which is why it is applied to lagging muscle groups rather than used for whole-body composition change.

Satellite cell activation via MAPK signalling adds myonuclei to existing fibres or supports differentiation into new fibres, the hyperplasia component that distinguishes IGF-1 biology from stimuli that only enlarge existing fibres.

The potency advantage translates into markedly lower effective amounts. In growth hormone deficient mice, 3 mcg of des(1-3)IGF-1 daily produced growth effects equivalent to 30 mcg of native IGF-1, a 10-fold dose advantage, alongside increased total body length and organ weights; kidney and heart weights rose relative to controls, which bears on the organ growth discussion around IGF-1 compounds.

Tomas and colleagues (1997) tested IGF-1 variants including des(1-3)IGF-1 in pigs and marmoset monkeys, finding them 2 to 3 times more potent than native IGF-1 at lowering blood glucose and showing 4 to 8 times greater cumulative hypoglycaemic effect over four hours, confirming that reduced IGFBP affinity translates to enhanced activity in vivo.

Secondary applications rest on IGF-1's established role in wound healing via fibroblast activity and collagen production, and on neurological research contexts including investigational interest in Rett syndrome and ALS. No published human clinical studies have used IGF-1 DES for muscle growth or performance.

No published clinical data establishes timelines for IGF-1 DES in healthy humans; the following reflects aggregated user reports rather than trial outcomes.

The most consistent report is an intense, tightly localised pump in the injected muscle when administered 15 to 30 minutes pre-workout, described as qualitatively distinct from a training pump or nitric oxide supplementation and attributed to rapid local IGF-1R activation with associated glucose uptake and blood flow.

Visible change in the targeted muscle group is typically reported after 2 to 3 weeks of consistent use. Rapid clearance means less water retention and systemic bloating than with IGF-1 LR3.

Use is generally confined to training days, injected into the muscle about to be trained or just trained. Cycle lengths cluster at 4 to 6 weeks, with some reporting shorter 3 to 4 week cycles. Receptor desensitisation is a lesser concern than with IGF-1 LR3 given the brief exposure, but cycling remains standard practice.

Timing preference is split. Pre-workout is favoured for pump and localised blood flow; post-workout is favoured for the satellite cell activation window following mechanical damage. Long-term results are reported as similar either way, and no published research favours one timing for this peptide.

Injection site redness, swelling and soreness are commonly reported, more so than with subcutaneous peptides, since delivery is directly into muscle. Hypoglycaemia is reported less often than with IGF-1 LR3 but still occurs, particularly at higher doses.

No published dose-finding studies exist for IGF-1 DES in healthy humans. Animal data is not translatable: the growth hormone deficient mouse study showed effects at 3 mcg daily, and the pig and marmoset work used varying infusion concentrations. The protocols below represent practice patterns rather than trial-derived dosing.

Standard practice is 50 to 100 mcg per injection, once daily on training days only, timed either 15 to 30 minutes pre-workout or within 15 minutes post-workout, with cycles of 4 to 6 weeks and 4 to 6 weeks off between cycles. A conservative entry protocol uses 20 to 50 mcg per injection, post-workout, over 4 weeks.

A site-specific variant splits the daily total across 2 to 4 injection sites, for example 50 mcg delivered as 25 mcg into each head of the biceps, administered 15 to 30 minutes before training that muscle.

Route matters more here than with longer-acting analogues. Intramuscular injection into the target muscle is preferred, since the 20 to 30 minute half-life means the peptide acts on adjacent tissue before clearance. Subcutaneous injection near the target is workable but delivers less direct muscle exposure; abdominal subcutaneous dosing largely defeats the purpose. Intramuscular delivery requires a slightly longer needle, typically 29 gauge, 0.5 inch, and appropriate depth for smaller muscle groups.

Reconstitution: 1 mg vial in 1 mL, giving 100 mcg per 10 units on an insulin syringe. A 0.6% acetic acid solution is preferred for stability; bacteriostatic water is also used but may reduce shelf life. Store at 2 to 8 C and use within 28 days. Some users reconstitute with acetic acid for stability and then draw the dose into a syringe pre-loaded with a small amount of bacteriostatic water to dilute the acid and reduce injection site burning.

Ceiling is 100 mcg total per day; higher doses increase side effect risk without proportional benefit. Hypoglycaemia risk persists despite rapid clearance, so fast-acting carbohydrates should be available. Somatostatin-mediated negative feedback means IGF-1 DES should not be run concurrently with growth hormone secretagogues.

Mechanistic and preclinical data on des(1-3)IGF-1 are consistent and well established; human clinical data for hypertrophy or performance are absent entirely.

Ballard et al., 1987 demonstrated that des(1-3)IGF-1 was approximately 7 times more potent than native IGF-1 at stimulating protein synthesis in L6 myoblasts, with essentially unchanged IGF-1R affinity. The potency gain derived from resistance to IGFBP sequestration rather than superior receptor binding.

Ross et al., 1989 supplied the mechanistic proof: IGFBPs inhibited DNA synthesis, protein accumulation and anti-proteolytic effects of IGF-1 and IGF-2 in culture, while des(1-3)IGF-1 was unaffected. Biological potency correlated inversely with binding protein affinity.

Ballard et al., 1996 revised the estimate to roughly 10-fold greater potency than IGF-1 at stimulating hypertrophy and proliferation of cultured cells, noting that enhanced effectiveness persists partially in vivo with notable anabolic effects in gut tissue, and that clinical applications remained unevaluated.

Tomas et al., 1997 tested IGF-1 variants including des(1-3)IGF-1 in pigs and marmoset monkeys. The variants were 2 to 3 times more potent than native IGF-1 at lowering blood glucose and showed 4 to 8 times greater cumulative hypoglycaemic effect over four hours, confirming that reduced IGFBP affinity translates into enhanced in vivo activity.

In growth hormone deficient mice, 3 mcg of des(1-3)IGF-1 daily produced growth effects equivalent to 30 mcg of native IGF-1, increasing total body length and organ weights; kidney and heart weights rose relative to controls, which bears on the organ growth safety discussion.

Supporting IGF-1 biology comes from Yoshida and Delafontaine 2020 on PI3K-Akt-mTOR and MAPK regulation of skeletal muscle, Barton-Davis et al., 1999 and Machida and Booth 2004 on satellite cell contribution, and Arvat et al., 1997 on GH autofeedback. The practical intramuscular protocols are extrapolation, not evidence.